Unknown

Dataset Information

0

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.


ABSTRACT:

Objective

Evaluate the effect of subcutaneous interferon β-1a (sc IFN β-1a) versus placebo on the evolution of T1-weighted MRI lesions and central brain atrophy in in patients with a first clinical demyelinating event (FCDE).

Methods

Post hoc analysis of baseline-to-24 month MRI data from patients with an FCDE who received sc IFN β-1a 44 μg once- (qw) or three-times-weekly (tiw), or placebo, in REFLEX. Patients were grouped according to treatment regimen or conversion to clinically definite MS (CDMS) status. The intensity of new lesions on unenhanced T1-weighted images was classified as T1 iso- or hypo-intense (black holes) and percentage ventricular volume change (PVVC) was assessed throughout the study.

Results

In patients not converting to CDMS, sc IFN β-1a tiw or qw, versus placebo, reduced the overall number of new lesions (P < 0.001 and P = 0.005) and new T1 iso-intense lesions (P < 0.001 and P = 0.002) after 24 months; only sc IFN β-1a tiw was associated with fewer T1 hypo-intense lesions versus placebo (P < 0.001). PVVC findings in patients treated with sc IFN β-1a suggested pseudo-atrophy that was ~ fivefold greater versus placebo in the first year of treatment (placebo 1.11%; qw 4.28%; tiw 6.76%; P < 001); similar findings were apparent for non-converting patients.

Conclusions

In patients with an FCDE, treatment with sc IFN β-1a tiw for 24 months reduced the number of new lesions evolving into black holes.

SUBMITTER: Vrenken H 

PROVIDER: S-EPMC10025187 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.

Vrenken H H   Battaglini M M   de Vos M L ML   Nagtegaal G J GJ   Teixeira B C A BCA   Seitzinger A A   Jack D D   Jack D D   Sormani M P MP   Uitdehaag B M J BMJ   Versteeg A A   Comi G G   Kappos L L   De Stefano N N   Barkhof F F  

Journal of neurology 20230201 4


<h4>Objective</h4>Evaluate the effect of subcutaneous interferon β-1a (sc IFN β-1a) versus placebo on the evolution of T1-weighted MRI lesions and central brain atrophy in in patients with a first clinical demyelinating event (FCDE).<h4>Methods</h4>Post hoc analysis of baseline-to-24 month MRI data from patients with an FCDE who received sc IFN β-1a 44 μg once- (qw) or three-times-weekly (tiw), or placebo, in REFLEX. Patients were grouped according to treatment regimen or conversion to clinicall  ...[more]

Similar Datasets

| S-EPMC3359505 | biostudies-literature
| S-EPMC10406195 | biostudies-literature
| S-EPMC11349618 | biostudies-literature
| S-EPMC10709839 | biostudies-literature
| S-EPMC4662880 | biostudies-literature
| S-EPMC9321632 | biostudies-literature
| S-EPMC7643814 | biostudies-literature
| S-EPMC7965580 | biostudies-literature
| S-EPMC8457117 | biostudies-literature
2016-07-03 | E-GEOD-60943 | biostudies-arrayexpress